• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miR-26a与多形性腺瘤基因1(PLAG1)在侵袭性垂体腺瘤中的表达及临床意义

Expression and Clinical Significance of miR-26a and Pleomorphic Adenoma Gene 1 (PLAG1) in Invasive Pituitary Adenoma.

作者信息

Yu ChuanTing, Li JiXia, Sun FengNan, Cui JinPeng, Fang HuaLi, Sui GuoLang

机构信息

Department of Clinical Laboratory, Yantaishan Hospital, Yantai, Shandong, China (mainland).

Department of Endocrinology, Yantaishan Hospital, Yantai, Shandong, China (mainland).

出版信息

Med Sci Monit. 2016 Dec 24;22:5101-5108. doi: 10.12659/msm.898908.

DOI:10.12659/msm.898908
PMID:28012286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5207015/
Abstract

BACKGROUND Although pituitary adenoma is a malignant tumor, it can present as invasive growth in some cases. MicroRNA (miR)-26a has been found to be abnormally highly expressed in pituitary adenoma, indicating possible involvement in pathogenesis. As a known target gene of miR-26a, PLAG1 has abnormally low expression in pituitary adenoma. The correlation between miR-26a or PLAG1 expressional abnormality and occurrence of pituitary adenoma is still unknown, as is its association with invasiveness of pituitary adenoma. MATERIAL AND METHODS Pituitary adenoma tissues, including both invasive and non-invasive subtypes, were collected from our Neurosurgery Department, in parallel with normal pituitary tissues from postmortem autopsy. qRT-PCR was used to detect mRNA expression of miR-26a and PLAG1, while Western blotting was used to test PLAG1 protein expression. The correlation between miR-26a and PLAG1, and with pathological features, were analyzed. ROC analysis revealed the utility of miR-26a and PLAG1 in differential diagnosis of invasive/non-invasive pituitary tumors and in analyzing their effects on patient prognosis. RESULTS MiR-26a was remarkably upregulated in pituitary tumors, while PLAG1 was downregulated, especially in invasive pituitary tumors. miR-26a and PLAG1 had higher diagnostic values for differentiating between invasive and non-invasive pituitary tumors (AUC=0.889 and 0.818, respectively). Those patients with miR-26 overexpression and PLAG1 downregulation had unfavorable prognosis. miR-26 and PLAG1 are independent factors affecting patient diagnosis. CONCLUSIONS MiR-26a can facilitate occurrence of pituitary tumor and invasiveness, probably via inhibiting PLAG1 expression.

摘要

背景

尽管垂体腺瘤是一种恶性肿瘤,但在某些情况下可呈侵袭性生长。已发现微小RNA(miR)-26a在垂体腺瘤中异常高表达,提示其可能参与发病机制。作为miR-26a的已知靶基因,PLAG1在垂体腺瘤中表达异常低。miR-26a或PLAG1表达异常与垂体腺瘤发生之间的相关性仍不清楚,其与垂体腺瘤侵袭性的关系也不明确。

材料与方法

从我院神经外科收集包括侵袭性和非侵袭性亚型的垂体腺瘤组织,并与尸检获得的正常垂体组织进行对照。采用qRT-PCR检测miR-26a和PLAG1的mRNA表达,同时用蛋白质印迹法检测PLAG1蛋白表达。分析miR-26a与PLAG1之间的相关性及其与病理特征的关系。ROC分析揭示了miR-26a和PLAG1在鉴别侵袭性/非侵袭性垂体肿瘤及分析其对患者预后影响方面的作用。

结果

miR-26a在垂体肿瘤中显著上调,而PLAG1下调,尤其是在侵袭性垂体肿瘤中。miR-26a和PLAG1在鉴别侵袭性和非侵袭性垂体肿瘤方面具有较高的诊断价值(AUC分别为0.889和0.818)。miR-26过表达和PLAG1下调的患者预后不良。miR-26和PLAG1是影响患者诊断的独立因素。

结论

miR-26a可能通过抑制PLAG1表达促进垂体肿瘤的发生和侵袭。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffe9/5207015/4c65c948c996/medscimonit-22-5101-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffe9/5207015/70bd8e8a738c/medscimonit-22-5101-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffe9/5207015/4e886f91e323/medscimonit-22-5101-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffe9/5207015/4c65c948c996/medscimonit-22-5101-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffe9/5207015/70bd8e8a738c/medscimonit-22-5101-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffe9/5207015/4e886f91e323/medscimonit-22-5101-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffe9/5207015/4c65c948c996/medscimonit-22-5101-g003.jpg

相似文献

1
Expression and Clinical Significance of miR-26a and Pleomorphic Adenoma Gene 1 (PLAG1) in Invasive Pituitary Adenoma.miR-26a与多形性腺瘤基因1(PLAG1)在侵袭性垂体腺瘤中的表达及临床意义
Med Sci Monit. 2016 Dec 24;22:5101-5108. doi: 10.12659/msm.898908.
2
Effect of miR-106b on Invasiveness of Pituitary Adenoma via PTEN-PI3K/AKT.miR-106b通过PTEN-PI3K/AKT对垂体腺瘤侵袭性的影响
Med Sci Monit. 2017 Mar 13;23:1277-1285. doi: 10.12659/msm.900092.
3
MiR-26a and miR-191 are upregulated while PLAG1 and HIF2 are downregulated in pleomorphic adenomas of the salivary glands compared to Warthin tumors.与沃辛瘤相比,唾液腺多形性腺瘤中 miR-26a 和 miR-191 的表达上调,而 PLAG1 和 HIF2 的表达下调。
J Oral Pathol Med. 2024 Aug;53(7):451-457. doi: 10.1111/jop.13565. Epub 2024 Jun 9.
4
Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile.通过分析微小RNA表达谱鉴定无功能侵袭性垂体腺瘤的新型生物标志物。
Biochem Genet. 2017 Jun;55(3):253-267. doi: 10.1007/s10528-017-9794-9. Epub 2017 Mar 17.
5
MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.微小RNA-106b通过靶向PTEN,经由PI3K/AKT信号通路促进垂体肿瘤细胞的增殖和侵袭。
Tumour Biol. 2016 Oct;37(10):13469-13477. doi: 10.1007/s13277-016-5155-2. Epub 2016 Jul 27.
6
Expression of cold-inducible RNA-binding protein (CIRP) in pituitary adenoma and its relationships with tumor recurrence.冷诱导RNA结合蛋白(CIRP)在垂体腺瘤中的表达及其与肿瘤复发的关系。
Med Sci Monit. 2015 May 2;21:1256-60. doi: 10.12659/MSM.893128.
7
Effects of microRNA-21 targeting PITX2 on proliferation and apoptosis of pituitary tumor cells.微小 RNA-21 靶向 PITX2 对垂体瘤细胞增殖和凋亡的影响。
Eur Rev Med Pharmacol Sci. 2017 Jul;21(13):2995-3004.
8
MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5.miR-132、miR-15a 和 miR-16 通过靶向 Sox5 协同抑制垂体瘤细胞增殖、侵袭和迁移。
Cancer Lett. 2015 Jan 28;356(2 Pt B):568-78. doi: 10.1016/j.canlet.2014.10.003. Epub 2014 Oct 8.
9
MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior.垂体瘤中的 microRNAs 表达:与功能状态、病理特征和临床行为相关的差异。
J Endocrinol Invest. 2020 Jul;43(7):947-958. doi: 10.1007/s40618-019-01178-4. Epub 2020 Jan 14.
10
MicroRNA-26a-5p inhibits breast cancer cell growth by suppressing RNF6 expression.microRNA-26a-5p 通过抑制 RNF6 表达抑制乳腺癌细胞生长。
Kaohsiung J Med Sci. 2019 Aug;35(8):467-473. doi: 10.1002/kjm2.12085. Epub 2019 May 7.

引用本文的文献

1
Comprehensive pan-cancer analysis identifies PLAG1 as a key regulator of tumor immune microenvironment and prognostic biomarker.全面的泛癌分析确定PLAG1是肿瘤免疫微环境的关键调节因子和预后生物标志物。
Front Immunol. 2025 Apr 10;16:1572108. doi: 10.3389/fimmu.2025.1572108. eCollection 2025.
2
MicroRNA-323a-3p Negatively Regulates NEK6 in Colon Adenocarcinoma Cells.微小RNA-323a-3p在结肠腺癌细胞中负向调控NEK6
J Oncol. 2022 Jan 19;2022:7007718. doi: 10.1155/2022/7007718. eCollection 2022.
3
Hyperglycemia induces miR-26-5p down-regulation to overexpress PFKFB3 and accelerate epithelial-mesenchymal transition in gastric cancer.

本文引用的文献

1
A case of unusual histology of infantile lipoblastoma confirmed by PLAG1 rearrangement.一例经PLAG1重排确诊的婴儿脂肪母细胞瘤罕见组织学病例。
Surg Case Rep. 2015 Dec;1(1):42. doi: 10.1186/s40792-015-0042-4. Epub 2015 May 16.
2
Clinicopathological prognostic and theranostic markers in pituitary tumors.垂体肿瘤的临床病理预后及诊疗标志物
Minerva Endocrinol. 2016 Sep;41(3):377-89. Epub 2016 Mar 4.
3
MicroRNA Targeting to Modulate Tumor Microenvironment.靶向微小RNA以调节肿瘤微环境。
高血糖诱导 miR-26-5p 下调以过表达 PFKFB3 并加速胃癌中的上皮-间充质转化。
Bioengineered. 2022 Feb;13(2):2902-2917. doi: 10.1080/21655979.2022.2026730.
4
The Emerging Role of Non-Coding RNAs in Pituitary Gland Tumors and Meningioma.非编码RNA在垂体瘤和脑膜瘤中的新兴作用
Cancers (Basel). 2021 Nov 28;13(23):5987. doi: 10.3390/cancers13235987.
5
Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.定量乙酰化组学揭示了人无功能性垂体神经内分泌肿瘤中乙酰化介导的分子通路网络变化。
Front Endocrinol (Lausanne). 2021 Oct 12;12:753606. doi: 10.3389/fendo.2021.753606. eCollection 2021.
6
The Role of MicroRNAs in Therapeutic Resistance of Malignant Primary Brain Tumors.微小RNA在恶性原发性脑肿瘤治疗耐药中的作用
Front Cell Dev Biol. 2021 Oct 7;9:740303. doi: 10.3389/fcell.2021.740303. eCollection 2021.
7
Up-regulation of sex-determining region Y-box 9 (SOX9) in growth hormone-secreting pituitary adenomas.生长激素型垂体腺瘤中性别决定区 Y 框 9(SOX9)的上调。
BMC Endocr Disord. 2021 Mar 18;21(1):50. doi: 10.1186/s12902-021-00720-x.
8
Multiple Endocrine Neoplasia Type 1: The Potential Role of microRNAs in the Management of the Syndrome.多发性内分泌腺瘤病 1 型:微小 RNA 在该综合征治疗中的潜在作用。
Int J Mol Sci. 2020 Oct 14;21(20):7592. doi: 10.3390/ijms21207592.
9
MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas.微小 RNA 作为垂体腺瘤的非侵入性生物标志物和治疗剂。
Int J Mol Sci. 2020 Oct 2;21(19):7287. doi: 10.3390/ijms21197287.
10
Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms.垂体肿瘤发生的新见解:遗传和表观遗传机制。
Endocr Rev. 2020 Dec 1;41(6):821-46. doi: 10.1210/endrev/bnaa006.
Front Oncol. 2016 Jan 19;6:3. doi: 10.3389/fonc.2016.00003. eCollection 2016.
4
Integrative proteomics and transcriptomics identify novel invasive-related biomarkers of non-functioning pituitary adenomas.整合蛋白质组学和转录组学鉴定无功能垂体腺瘤新的侵袭相关生物标志物。
Tumour Biol. 2016 Jul;37(7):8923-30. doi: 10.1007/s13277-015-4767-2. Epub 2016 Jan 11.
5
MicroRNA-induced cascaded and catalytic self-assembly of DNA nanostructures for enzyme-free and sensitive fluorescence detection of microRNA from tumor cells.用于无酶且灵敏荧光检测肿瘤细胞中微小RNA的DNA纳米结构的微小RNA诱导级联催化自组装
Chem Commun (Camb). 2016 Feb 11;52(12):2501-4. doi: 10.1039/c5cc08861e. Epub 2016 Jan 7.
6
[The Role of Cancer-associated Fibroblasts in Invasive Behavior of Pituitary Adenoma].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2015 Sep;46(5):673-8.
7
Effect of Hypoxia on DDR1 Expression in Pituitary Adenomas.缺氧对垂体腺瘤中DDR1表达的影响。
Med Sci Monit. 2015 Aug 19;21:2433-8. doi: 10.12659/MSM.894205.
8
Expression of cold-inducible RNA-binding protein (CIRP) in pituitary adenoma and its relationships with tumor recurrence.冷诱导RNA结合蛋白(CIRP)在垂体腺瘤中的表达及其与肿瘤复发的关系。
Med Sci Monit. 2015 May 2;21:1256-60. doi: 10.12659/MSM.893128.
9
Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: long-term clinical outcomes and volumetric MRI assessment of tumor response.大侵袭性无功能垂体腺瘤的分次立体定向放疗:长期临床结果和肿瘤反应的容积 MRI 评估。
Eur J Endocrinol. 2015 Apr;172(4):433-41. doi: 10.1530/EJE-14-0872. Epub 2015 Jan 27.
10
Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts.一致的PLAG1和HMGA2异常可将多形性腺瘤癌变与其原发性对应物区分开来。
Hum Pathol. 2015 Jan;46(1):26-33. doi: 10.1016/j.humpath.2014.08.017. Epub 2014 Sep 7.